Author:
Guimbellot Jennifer S.,Nichols David P.,Brewington John J.
Funder
National Institutes of Health
Cystic Fibrosis Foundation
Subject
Pulmonary and Respiratory Medicine,General Medicine
Reference143 articles.
1. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation;Accurso;N Engl J Med,2010
2. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial;Heijerman,2019
3. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele;Middleton;N Engl J Med,2019
4. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation;Ramsey;N Engl J Med,2011
5. Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis;Rowe;N Engl J Med,2017
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献